Xianda Zhao

MICaB Ph.D. Student

Education:

B.M., Wuhan University, Wuhan, China, 2014

Research: 

Advances in immunotherapy have led to a paradigm shift in the treatment of cancers. Remarkable clinical responses have achieved in certain patients after immune checkpoint blockade therapy. However, one of the biggest challenges in cancer therapeutics is intrinsic resistance, i.e. insensitivity of treatment. My research goals are understanding the mechanisms of intrinsic resistance to immune checkpoint blockade therapies and investigating novel combinational treatments to release the resistance in pre-clinical cancer models.

Publications:

S. Banerjee, S. Modi, O. McGinn, X. Zhao, V. Dudeja, S. Ramakrishnan, A. Saluja. 2016. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer. Clin Cancer Res 15;22(2):415-25.

R.I. Vogel, T. Pulver, W. Heilmann, A. Mooneyham, S. Mullany, X. Zhao, M. Shahi, J. Richter, M. Klein, L. Chen, R. Ding, G. Konecny, S. Kommoss, B. Winterhoff, R. Ghebre, M. Bazzaro. 2016. USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment. Oncotarget [Epub ahead of print]

Xianda Zhao